DC Advisory (DC) advised Taisho Pharmaceutical on its acquisition of a 24.5% stake in Duoc Hau Giang Pharmaceutical JSC as well as on a further acquisition of up to 51.0% stake.

The investment in Duoc Hau Giang Pharmaceutical JSC is part of Taisho’s efforts to strengthen its competitiveness in the global market, especially in Southeast Asia.

DC had previously advised the acquirer, Taisho, on its acquisition of Southeast Asian operations of Bristol-Myers Squibb Co.

DHG is the largest Vietnamese domestic pharmaceutical company.

Taisho is principally involved in self-medication business achieved through over-the-counter medicines, health-related products, and prescription pharmaceuticals.

Taisho believes that the transaction and alliance will enable it to share its technology, and know-how in the pharmaceutical business with DHG, resulting in an increase in DHG’s sales and further growth of Taisho’s and DHG’s businesses in Asia.

In addition, Taisho anticipates the creation of synergies between DHG, with its strong presence in Vietnam, and Taisho.

DHG believes that the Alliance will open up opportunities for cooperation, partnership and JV in production, R&D, and trading in the future.